The World's First Selective-Dose Pharmaceutical Grade Medicinal Plants Inhaler
We finally may have a delivery system for medical cannabis that is effective, stable, safe and easy to use.Journal of Pain & Palliative Care Pharmacotherapy - Reviewer
Raw Plant
Standardized Production
Pharmaceutical Grade
Structural Modification
No Chemical Alteration
No Added Excipients
Preloaded Cartridges
Uniquely Identified
Childproof
Metered-Dose Delivery
100 Microgram Resolution
Selective Dosing
-
Journal of Pain & Palliative Care Pharmacotherapy – ReviewerWe finally may have a delivery system for medical cannabis that is effective, stable, safe and easy to use
-
The Wall Street JournalDoctor-prescribed joints might one day become a relic of the past if cannabis technology venture Syqe Medical Ltd. has its way.
-
Senior government officialThis is the perfect solution to all the challenges today in the cannabis field
-
Bloomberg TVIsraeli start-up may be set to revolutionize the way cannabis is taken by patients suffering from severe pain
-
FastCompany: The World’s Most Innovative Companies 2017…another step toward marijuana becoming a normal part of the drug cabinet
-
FiercePharmaTeva inks trailblazing cannabis pact with Israel’s Syqe Medical
-
BloombergIsraeli Cannabis Inhaler May Get Tested With Opium Poppy Next
-
Financial TimesIsrael has high hopes for its nascent medical marijuana sector
Syqe Inhaler Exo® (For Hospital Use)
A hospital version selective-dose cannabis inhaler for professional healthcare use, featuring a caregiver interface. Aimed at providing nurses and caregivers with a certified medical device for use in pain clinics, cancer centers, intensive care units and other medical institutions. The Syqe Inhaler Exo is available for hospital use in Israel.
Clinical
Clinical trials are at the forefront of our strategy, providing clinical evidence and leveraging the full potential of our technology. Our recent trial demonstrated the feasibility and the first-in-class positioning of our inhaler platform. The objective of the study was to assess the potential of the Syqe Inhaler Exo in terms of pharmacokinetics, accuracy of dosing, safety, tolerability, efficacy and ease of use. This trial suggests the potential use of the Syqe Inhaler Platform, producing a Δ⁹-THC pharmacokinetic profile with low-interindividual variation of Cmax, achieving pharmaceutical standards for inhaled drugs.
Journal of Pain & Palliative Care PharmacotherapyThe Pharmacokinetics, Efficacy, Safety, and Ease of Use of a Novel Portable Metered-Dose Cannabis Inhaler in Patients With Chronic Neuropathic Pain: A Phase 1a StudyElon Eisenberg, Miri Ogintz, and Shlomo Almog
September 2014, Vol. 28, No. 3
Dosing Precision (Interindividual Variability)
Interindividual variability of Δ⁹-THC plasma Cmax obtained by various modes of delivery.
Dosing Precision (Inter - individual variability)
Source: Eisenberg et al. The PK, efficacy, safety and ease of use of a novel portable metered-dose cannabis inhaler in a cohort of patients with chronic neuropathic pain - 2014.
* Average inter-individual CV of referenced clinical studies.
† Kavita Gumbhir-Shah et al. PK and PD of Cumaltive Single Doses of Inhaled Salbutamol 1999
† Paula J. Anderson et al. PK of (R,S)-Albuterol after Aerosol Inhalation in Healthy Adult Volunteers 1998
Efficiency (ng/ml per mg)
Δ⁹-THC plasma Cmax levels per mg administered by various modes of delivery.
Efficiency ng/ml per mg delta9-THC
Source: Eisenberg et al. The PK, efficacy, safety and ease of use of a novel portable metered-dose cannabis inhaler in a cohort of patients with chronic neuropathic pain - 2014.
* Average Plasma Cmax of referenced clinical studies.
Pharmacokinetic Data (Syqe Inhaler Exo)
Δ⁹-THC plasma levels following single-dose inhalation of 15.1 ± 0.1 mg cannabis flos
Pharmacokinetic Data (Syqe Inhaler Exo)
| Cmax (ng/ml) | Tmax (min) | AUC (ng∙min/ml) | |
|---|---|---|---|
| Mean | 38 | 3 | 607 |
| SD | 10 | 1 | 200 |
In the study, 15.1mg ± 0.1 of Cannabis 19.9% THC (Bedrocan) was administered using the Syqe Inhaler Exo in a single inhalation to 10 chronic pain patients (2 excluded). In addition, there was robust pain relief (VAS scale) following a single inhalation lasting up to 90 minutes.
Clinical Goal
Accurately enter the therapeutic window and seamlessly maintain it.
Clinical Goal
Accurately enter the therapeutic window between Psychoactivity and Symptom relief, while seamlessly maintaining it.
About Us
Syqe Medical aspires to transform cannabis and other botanicals into mainstream medical drugs. Our vision is to decentralize drug development and streamline its clinical testing in a 21st century fashion. To achieve these goals our company has been implementing cutting-edge technologies for over 5 years and employs a multi-disciplinary team of electronic engineers, mechanical engineers, industrial designers, chemists, biologists, physicians and Pharmacologists.Management
Eytan Hyam is Syqe’s Chairman of the Board. Eytan is a former Director-General of Israel’s Ministry of Health, and the Soroka and Assuta Medical Centers. An ex-director of Clalit HMO central district, Eytan is a qualified general practitioner, and graduate of Israel’s Ben Gurion Medical School, Beer Sheva.
Perry Davidson is the Founder and CEO of Syqe Medical. An inventor of patents in various fields, including the company’s core technology, Perry was Co-founder and former CEO of Israel’s largest medical cannabis production company. He has more than a decade’s experience in controlled substance regulation and state implementation.
James Amihood is Syqe’s General Manager. A South African by birth, James has 25 years of management experience, holding senior positions at global, Nasdaq-traded healthcare companies, managing subsidiaries and heading Business Development. James holds an MBA, B.Sc. in Chemistry, and a B.Sc. in industrial engineering.
Revital Rodovsky is Syqe’s CFO. With almost 15 years’ executive experience, Revital served as CFO for a number of tech companies in the medical device and communication spaces, successfully leading a string of mergers and acquisitions. Revital holds a certified public accountant diploma and a BA in Business Management.
Daniella Atzmony is Syqe’s chief intellectual property officer and general counsel, responsible for legal and IP issues. An advocate and patent attorney, Daniella previously worked at one of Israel’s largest patent firms, and has provided in-house IP advice to a number of start-ups. Daniella holds a PhD in Biology, and chairs Israel’s In-House IP Managers Forum.
Lea Lak is Syqe’s Medical Director, responsible for clinical trials and regulatory matters. Lea has led teams in multiple medical device companies, heading research and clinical trials in challenging, multi-disciplinary projects: as Medical Director of CorAssist, Medical Manager of Polyheal and Medical Specialist at ByPass. Lea is a graduate of Hadassah Medical School, Jerusalem.
Benjamin Schwartz leads Syqe’s multidisciplinary R&D team. An electronics engineer by trade, he’s led a number of projects for defence companies, such as Rafael and Elbit, focusing on aviation and special forces’ technologies. Benny was one of Syqe’s first employees.
Seth Kindler is Syqe’s Chief Science Officer. A psychiatrist with more than 20 years’ experience in the biopharmaceutical sector, Seth served as Medical Director at Pharmos, and consulted for several cannabis-based startups. Seth is a former Deputy Director of the Sheba Hospital’s Psychiatric Ward, and headed the Israeli Army’s PTSD Clinical Research Program.
Elon Eisenberg heads up Syqe’s Scientific Advisory Board for Pain Management, and sits on the Executive Board of the European Pain Federation. Elon leads the Pain Research Unit at Rambam Medical Center. He’s also an associate professor of Neurology & Pain at the Technion.
Brian Cooper is a member of Syqe’s Executive Board, and co-founder investor. Brian is the founder and former CFO of retail software company, Retalix, which was sold to NCR for $650m. He’s an active Angel and early-stage investor in a number of IT and Life Science companies.